Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
- PMID: 16186598
- DOI: 10.1200/JCO.2005.01.7038
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
Abstract
Purpose: The aim of this study was to evaluate the prognostic value of the WHO proposal, to assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) classified into WHO subgroups, and to estimate mortality (standardized mortality ratio [SMR]) and life expectancy in these groups as a basis for clinical decision making.
Patients and methods: Four hundred sixty-seven patients who were diagnosed as having de novo MDS at the Division of Hematology, University of Pavia (Pavia, Italy), between 1992 and 2002, were evaluated retrospectively for clinical and hematologic features at diagnosis, overall survival (OS), and progression to leukemia (leukemia-free survival).
Results: Significant differences in survival were noted between patients with refractory anemia (RA), refractory cytopenia with multilineage dysplasia, RA with excess blasts, type 1 (RAEB-1), and RAEB-2. The effect of demographic factors on OS was observed in MDS patients without excess blasts (age, P = .001; sex, P = .006), as in the general population. The mortality of RA patients 70 years or older did not differ significantly from that of the general population (SMR, 1.62; P = .06). Cytogenetics was the only International Prognostic Scoring System variable showing a prognostic value in MDS classified into WHO subgroups. Transfusion-dependent patients had a significantly shorter survival than patients who did not require transfusions (P < .001). Developing a secondary iron overload significantly affected the survival of transfusion-dependent patients (P = .003).
Conclusion: These data show that the WHO classification of MDSs has a relevant prognostic value. This classification, along with cytogenetics, might be useful in decisions regarding transplantation. MDS with isolated erythroid lineage dysplasia identifies a subset of truly low-risk patients, for whom a conservative approach is advisable.
Similar articles
-
Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.Ann Hematol. 2006 Aug;85(8):502-13. doi: 10.1007/s00277-005-0030-z. Epub 2006 May 20. Ann Hematol. 2006. PMID: 16715299
-
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.J Clin Oncol. 2009 Feb 10;27(5):754-62. doi: 10.1200/JCO.2008.18.2246. Epub 2008 Dec 22. J Clin Oncol. 2009. PMID: 19103730
-
Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.Leuk Res. 2006 Aug;30(8):971-7. doi: 10.1016/j.leukres.2005.11.015. Epub 2006 Jan 19. Leuk Res. 2006. PMID: 16423393
-
Acute erythroid neoplastic proliferations. A biological study based on 62 patients.Haematologica. 2002 Feb;87(2):148-53. Haematologica. 2002. PMID: 11836165 Review.
-
A comparative review of classification systems in myelodysplastic syndromes (MDS).Semin Oncol. 2005 Aug;32(4 Suppl 5):S3-10. doi: 10.1053/j.seminoncol.2005.06.021. Semin Oncol. 2005. PMID: 16085011 Review.
Cited by
-
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27. Leukemia. 2015. PMID: 25721895
-
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome.J Immunol. 2012 Sep 15;189(6):3198-208. doi: 10.4049/jimmunol.1200602. Epub 2012 Aug 8. J Immunol. 2012. PMID: 22875800 Free PMC article.
-
Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.Stem Cell Investig. 2014 Aug 21;1:16. doi: 10.3978/j.issn.2306-9759.2014.08.02. eCollection 2014. Stem Cell Investig. 2014. PMID: 27358862 Free PMC article. Review.
-
The revolution of myelodysplastic syndromes.Ther Adv Hematol. 2011 Feb;2(1):33-43. doi: 10.1177/2040620710395652. Ther Adv Hematol. 2011. PMID: 23556074 Free PMC article.
-
Controversies on the Consequences of Iron Overload and Chelation in MDS.Hemasphere. 2020 May 27;4(3):e357. doi: 10.1097/HS9.0000000000000357. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647792 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous